NCT00516516

Brief Summary

Muscle cramps occur frequently among pregnant women, and few therapeutic options exist. This is a study of oral L-carnitine, a dietary supplement, for the treatment of muscle cramps in pregnancy. Our hypothesis is that carnitine will alleviate or eliminate muscle cramps experienced by pregnant women.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jul 2008

Geographic Reach
1 country

3 active sites

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 14, 2007

Completed
1 day until next milestone

First Posted

Study publicly available on registry

August 15, 2007

Completed
11 months until next milestone

Study Start

First participant enrolled

July 1, 2008

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2009

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2009

Completed
Last Updated

April 20, 2017

Status Verified

October 1, 2009

Enrollment Period

11 months

First QC Date

August 14, 2007

Last Update Submit

April 18, 2017

Conditions

Keywords

muscle cramppregnancycarnitinerandomized controlled clinical trials

Outcome Measures

Primary Outcomes (1)

  • Complete elimination of muscle cramps

    4 weeks

Study Arms (2)

I

EXPERIMENTAL

Oral L-Carnitine, 1g PO twice daily

Dietary Supplement: L-Carnitine

II

PLACEBO COMPARATOR

Placebo, similar in appearance to experimental drug, given orally twice daily.

Dietary Supplement: Placebo

Interventions

L-CarnitineDIETARY_SUPPLEMENT

L-Carnitine, 1g orally, twice daily

I
PlaceboDIETARY_SUPPLEMENT

Placebo, similar in appearance to study tablets, given orally, twice daily.

II

Eligibility Criteria

Age16 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Age 16 or older
  • Gestational Age 12 to 33 weeks
  • Occurrence of muscle cramps at least once weekly
  • Ability to tolerate oral L-Carnitine
  • Ability / willingness to provide informed consent in English or Spanish

You may not qualify if:

  • Prior treatment for muscle cramps during this pregnancy
  • Chronic muscle cramps prior to pregnancy
  • Magnesium administration beyond that contained in prenatal vitamins
  • History of seizures
  • History of Pre-term delivery before 36 weeks gestational age
  • Inability to tolerate oral L-Carnitine (e.g. hyperemesis gravidarum)
  • Inability or unwillingness to provide informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

USC Perinatal Group Medical Office

Los Angeles, California, 90015, United States

Location

USC Perinatal Group Medical Office

Los Angeles, California, 90027, United States

Location

Women's & Children's Hospital Midwife Clinic

Los Angeles, California, 90033, United States

Location

MeSH Terms

Conditions

Muscle Cramp

Interventions

Carnitine

Condition Hierarchy (Ancestors)

Muscular DiseasesMusculoskeletal DiseasesNeuromuscular ManifestationsNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Trimethyl Ammonium CompoundsQuaternary Ammonium CompoundsAminesOrganic Chemicals

Study Officials

  • Emiliano R Chavira, MD,MPH

    University of Southern California, Keck School of Medicine, Division of Maternal-Fetal Medicine

    PRINCIPAL INVESTIGATOR
  • Thomas M Goodwin, MD

    University of Southern California, Keck School of Medicine, Division of Maternal-Fetal Medicine

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 14, 2007

First Posted

August 15, 2007

Study Start

July 1, 2008

Primary Completion

June 1, 2009

Study Completion

July 1, 2009

Last Updated

April 20, 2017

Record last verified: 2009-10

Locations